Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976

Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine.

M J Dobersen, M Jerkofsky, S Greer
PMCID: PMC355015  PMID: 185427

Abstract

5-Bromodeoxycytidine (BrdC) and 5-iododeoxycytidine, at a concentration of 100 mug/ml, effectively inhibit the replication of varicella-zoster (VZ) virus in tissue culture. No toxicity could be demonstrated in uninfected cells under the same conditions. Studies on the enzymatic basis for this selective inhibition were undertaken. Infection of human embryonic lung cell monolayers with VZ virus-infected cells results in the induction of thymidine (dT), deoxycytidine (dC), and BrdC kinase activities (which are increased 10-, 40-, and 60-fold, respectively) and in a 70-fold stimulation in the incorporation of 3H nucleotide (5-bromodeoxyuridylate) derived from BrdC into DNA. The thermal stability of the VZ virus-induced activities differs significantly from the activities induced by herpes simplex virus type 1 and herpes simplex virus type 2 and those present in uninfected human embryonic lung cells. The VZ virus-induced dT, dC, and BrdC kinase are similarly affected by temperature and cofractionate upon Sephadex gel filtration, findings consistent with the hypothesis that these activities are the function of a single enzyme: a pyrimidine deoxyribonucleoside kinase. The molecular weight, calculated on the basis of the elution pattern on Sephadex G-150, is 70,000. Kinetic studies, demonstrating that dT and dC competively inhibit the phosphorylation of BrdC, are consistent with the phosphorylation of these substrates at a common active site. Kinetic parameters include: KidT = 0.6 MUM; KidC = 60 muM; KmBrdC = 8.5 muM. In contrast to its relatively high affinity for the VZ virus-induced kinase, BrdC is a relatively poor substrate for the host kinases. Therefore, the basis for the selective inhibition of VZ virus by 5-halogenated analogues of dC is reflected in the induction of a pyrimidine deoxyribonucleoside kinase with a high affinity for BrdC.

Full text

PDF
478

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. Estimation of the molecular weights of proteins by Sephadex gel-filtration. Biochem J. 1964 May;91(2):222–233. doi: 10.1042/bj0910222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baron M., Wechsler H. L. Low-dosage cytarabine therapy for herpes zoster with pneumonia. Arch Dermatol. 1975 Jul;111(7):910–912. [PubMed] [Google Scholar]
  3. Bresnick E., Thompson U. B. Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem. 1965 Oct;240(10):3967–3974. [PubMed] [Google Scholar]
  4. Camiener G. W. Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol. 1968 Sep;17(9):1981–1991. doi: 10.1016/0006-2952(68)90114-7. [DOI] [PubMed] [Google Scholar]
  5. Cooper G. M., Greer S. Phosphorylation of 5-halogenated deoxycytidine analogues by deoxycytidine kinase. Mol Pharmacol. 1973 Nov;9(6):704–710. [PubMed] [Google Scholar]
  6. Cooper G. M. Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3788–3792. doi: 10.1073/pnas.70.12.3788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DUBBS D. R., KIT S. ISOLATION AND PROPERTIES OF VACCINIA MUTANTS DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY. Virology. 1964 Feb;22:214–225. doi: 10.1016/0042-6822(64)90006-6. [DOI] [PubMed] [Google Scholar]
  8. DUBBS D. R., KIT S. MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY. Virology. 1964 Apr;22:493–502. doi: 10.1016/0042-6822(64)90070-4. [DOI] [PubMed] [Google Scholar]
  9. Davis C. M., VanDersarl J. V., Coltman C. A., Jr Failure of cytarabine in varicella-zoster infections. JAMA. 1973 Apr 2;224(1):122–123. [PubMed] [Google Scholar]
  10. De Clercq E., Shugar D. Antiviral activity of 5-ethyl pyrimidine deoxynucleosides. Biochem Pharmacol. 1975 May 15;24(10):1073–1078. doi: 10.1016/0006-2952(75)90192-6. [DOI] [PubMed] [Google Scholar]
  11. De Clercq E., Torrence P. F., Waters J. A., Witkop B. Antiviral activity of 5-thiocyanatopyrimidine nucleosides. Biochem Pharmacol. 1975 Dec 1;24(23):2171–2175. doi: 10.1016/0006-2952(75)90049-0. [DOI] [PubMed] [Google Scholar]
  12. Gauri K. K., Malorny G. Chemotherapie der Herpes-Infektion mit neuen 5-Alkyluracildesoxyribosiden. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1967;257(1):21–22. [PubMed] [Google Scholar]
  13. Gauri K. K., Walter R. D. Inhibition of deoxythymidine kinase activity by the virostatic 5-ethyl-2'-deoxyuridine. Chemotherapy. 1973;18(5):269–273. doi: 10.1159/000221271. [DOI] [PubMed] [Google Scholar]
  14. Gentry G. A., Aswell J. F. Inhibition of herpes simplex virus replication by araT. Virology. 1975 May;65(1):294–296. doi: 10.1016/0042-6822(75)90034-3. [DOI] [PubMed] [Google Scholar]
  15. Goffinet D. R., Glatstein E. J., Merigan T. C. Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med. 1972 Feb;76(2):235–240. doi: 10.7326/0003-4819-76-2-235. [DOI] [PubMed] [Google Scholar]
  16. HOPE-SIMPSON R. E. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med. 1965 Jan;58:9–20. [PMC free article] [PubMed] [Google Scholar]
  17. Hay J., Perera P. A., Morrison J. M., Gentry G. A., Subak-Sharpe J. H. Herpes virus-specified proteins. In: strategy of the viral genome. Ciba Found Symp. 1971:355–376. [PubMed] [Google Scholar]
  18. Honess R. W., Watson D. H. Herpes simplex virus-specific polypeptides studied by polyacrylamide gel electrophoresis of immune precipitates. J Gen Virol. 1974 Feb;22(2):171–185. doi: 10.1099/0022-1317-22-2-171. [DOI] [PubMed] [Google Scholar]
  19. Jamieson A. T., Gentry G. A., Subak-Sharpe J. H. Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J Gen Virol. 1974 Sep;24(3):465–480. doi: 10.1099/0022-1317-24-3-465. [DOI] [PubMed] [Google Scholar]
  20. Jamieson A. T., Subak-Sharpe J. H. Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity. J Gen Virol. 1974 Sep;24(3):481–492. doi: 10.1099/0022-1317-24-3-481. [DOI] [PubMed] [Google Scholar]
  21. Johnson M. T., Buchanan R. A., Luby J. P., Mikulec D. Treatment of varicella-zoster virus infections with adenine arabinoside. J Infect Dis. 1975 Mar;131(3):225–229. doi: 10.1093/infdis/131.3.225. [DOI] [PubMed] [Google Scholar]
  22. Juel-Jensen B. E., MacCallum F. O., Mackenzie A. M., Pike M. C. Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials. Br Med J. 1970 Dec 26;4(5738):776–780. doi: 10.1136/bmj.4.5738.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kaplan A. S., Benporat T., Kamiya T. Incorporation of 5-bromodeoxyuridine and 5-iododeoxyuridine into viral DNA and its effect on the infective process. Ann N Y Acad Sci. 1965 Jul 30;130(1):226–239. doi: 10.1111/j.1749-6632.1965.tb12556.x. [DOI] [PubMed] [Google Scholar]
  24. Kessel D. Properties of deoxycytidine kinase partially purified from L1210 cells. J Biol Chem. 1968 Sep 25;243(18):4739–4744. [PubMed] [Google Scholar]
  25. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  26. Leung W. C., Dubbs D. R., Trkula D., Kit S. Mitochondrial and herpesvirus-specific deoxypyrimidine kinases. J Virol. 1975 Sep;16(3):486–497. doi: 10.1128/jvi.16.3.486-497.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. MERSELIS J. G., Jr, KAYE D., HOOK E. W. DISSEMINATED HERPES ZOSTER. A REPORT OF 17 CASES. Arch Intern Med. 1964 May;113:679–686. doi: 10.1001/archinte.1964.00280110059012. [DOI] [PubMed] [Google Scholar]
  28. Meuth M., Green H. Induction of a deoxycytidineless state in cultured mammalian cells by bromodeoxyuridine. Cell. 1974 Jun;2(2):109–112. doi: 10.1016/0092-8674(74)90099-3. [DOI] [PubMed] [Google Scholar]
  29. NEMES M. M., HILLEMAN M. R. EFFECTIVE TREATMENT OF EXPERIMENTAL HERPES SIMPLEX KERATITIS WITH NEW DERIVATIVE, 5-METHYLAMINO-2'-DEOXYURIDINE (MADU). Proc Soc Exp Biol Med. 1965 Jun;119:515–520. doi: 10.3181/00379727-119-30224. [DOI] [PubMed] [Google Scholar]
  30. OKAZAKI R., KORNBERG A. DEOXYTHYMIDINE KINASE OF ESCHERICHIA COLI. I. PURIFICATION AND SOME PROPERTIES OF THE ENZYME. J Biol Chem. 1964 Jan;239:269–274. [PubMed] [Google Scholar]
  31. OYAMA V. I., EAGLE H. Measurement of cell growth in tissue culture with a phenol reagent (folin-ciocalteau). Proc Soc Exp Biol Med. 1956 Feb;91(2):305–307. doi: 10.3181/00379727-91-22245. [DOI] [PubMed] [Google Scholar]
  32. Ogino T., Shiman R., Rapp F. Deoxythymidine kinase from rabbit kidney cells infected with herpes simplex virus types 1 and 2. Intervirology. 1973;1(2):80–95. doi: 10.1159/000148835. [DOI] [PubMed] [Google Scholar]
  33. RAPP F., VANDERSLICE D. SPREAD OF ZOSTER VIRUS IN HUMAN EMBRYONIC LUNG CELLS AND THE INHIBITORY EFFECT OF LODODEOXYURIDINE. Virology. 1964 Mar;22:321–330. doi: 10.1016/0042-6822(64)90023-6. [DOI] [PubMed] [Google Scholar]
  34. RAWLS W. E., COHEN R. A., HERRMANN E. C., Jr INHIBITION OF VARICELLA VIRUS BY 5-IODO-2'-DEOXYURIDINE. Proc Soc Exp Biol Med. 1964 Jan;115:123–127. doi: 10.3181/00379727-115-28848. [DOI] [PubMed] [Google Scholar]
  35. Rifkind D. The activation of varicella-zoster virus infections by immunosuppressive therapy. J Lab Clin Med. 1966 Sep;68(3):463–474. [PubMed] [Google Scholar]
  36. Russell W. C., Newman C., Williamson D. H. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature. 1975 Feb 6;253(5491):461–462. doi: 10.1038/253461a0. [DOI] [PubMed] [Google Scholar]
  37. Schildkraut I., Cooper G. M., Greer S. Selective inhibition of the replication of herpes simplex virus by 5-halogenated analogues of deoxycytidine. Mol Pharmacol. 1975 Mar;11(2):153–158. [PubMed] [Google Scholar]
  38. Schimpff S. C., Fortner C. L., Greene W. H., Wiernik P. H. Cytosine arabinoside for localized herpes zoster in patients with cancer: failure in a controlled trial. J Infect Dis. 1974 Dec;130(6):673–676. doi: 10.1093/infdis/130.6.673. [DOI] [PubMed] [Google Scholar]
  39. Schimpff S., Serpick A., Stoler B., Rumack B., Mellin H., Joseph J. M., Block J. Varicella-Zoster infection in patients with cancer. Ann Intern Med. 1972 Feb;76(2):241–254. doi: 10.7326/0003-4819-76-2-241. [DOI] [PubMed] [Google Scholar]
  40. Shen T. Y., McPherson J. F., Linn B. O. Nucleosides. 3. Studies on 5-methylamino-2'-deoxyuridine as a specific antiherpes agent. J Med Chem. 1966 May;9(3):366–369. doi: 10.1021/jm00321a025. [DOI] [PubMed] [Google Scholar]
  41. Stevens D. A., Jordan G. W., Waddell T. F., Merigan T. C. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med. 1973 Oct 25;289(17):873–878. doi: 10.1056/NEJM197310252891701. [DOI] [PubMed] [Google Scholar]
  42. Thouless M. E., Wildy P. Deoxypyrimidine kinases of herpes simplex viruses types 1 and 2: comparison of serological and structural properties. J Gen Virol. 1975 Feb;26(2):159–170. doi: 10.1099/0022-1317-26-2-159. [DOI] [PubMed] [Google Scholar]
  43. WELLER T. H., WITTON H. M., BELL E. J. The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro. J Exp Med. 1958 Dec 1;108(6):843–868. doi: 10.1084/jem.108.6.843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES